Quick Answer
Journey Medical Corp reported Cash and Equivalents of $24.09 million for fiscal year 2025.
Journey Medical Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $24.09M | +18.6% |
| 2024 | $20.30M | -26.0% |
| 2023 | $27.44M | -14.3% |
| 2022 | $32.00M | -34.8% |
| 2021 | $49.08M | +495.2% |
| 2020 | $8.25M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.95M | +11.1% | +22.9% |
| June 30, 2025 | $20.29M | -15.1% | -3.7% |
| March 31, 2025 | $21.07M | -12.4% | +3.8% |
| December 31, 2024 | $20.30M | -26.0% | -9.6% |
| September 30, 2024 | $22.46M | -9.2% | -6.1% |
| June 30, 2024 | $23.91M | +190.5% | -0.6% |
| March 31, 2024 | $24.06M | +38.7% | -12.3% |
| December 31, 2023 | $27.44M | -14.3% | +10.9% |
- Journey Medical Corp showed an increase of +18.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Journey Medical Corp’s cash and equivalents has grown by 192.1% (from $8.25 million to $24.09 million).
- The most recent figure is from Journey Medical Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: